Current Value
$14.301 Year Return
Current Value
$14.301 Year Return
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| PHAT | 42.46% | $596.21M | -30.11% | 0.00% |
| CVAC | 38.89% | $1.22B | +51.97% | 0.00% |
| VYGR | 34.16% | $170.16M | -66.17% | 0.00% |
| ATXS | 33.84% | $356.10M | -46.71% | 0.00% |
| OCUL | 31.80% | $1.77B | +32.02% | 0.00% |
| RVMD | 31.78% | $7.04B | -19.16% | 0.00% |
| MANU | 31.45% | $3.01B | +2.68% | 0.00% |
| CELC | 30.99% | $521.80M | -26.27% | 0.00% |
| COGT | 30.99% | $1.60B | +21.05% | 0.00% |
| LEGN | 30.76% | $7.29B | -29.18% | 0.00% |
| XNCR | 30.75% | $600.68M | -58.69% | 0.00% |
| RXRX | 29.77% | $2.26B | -39.30% | 0.00% |
| IDYA | 29.73% | $1.88B | -49.75% | 0.00% |
| AMRX | 29.56% | $2.59B | +8.82% | 0.00% |
| ESRT | 29.07% | $1.34B | -25.44% | 1.74% |
| ZYME | 28.91% | $904.86M | +24.44% | 0.00% |
| CLDX | 28.64% | $1.52B | -42.85% | 0.00% |
| IOVA | 28.61% | $647.83M | -79.38% | 0.00% |
| IMNM | 28.59% | $730.90M | -42.70% | 0.00% |
| CRNX | 28.29% | $2.98B | -42.11% | 0.00% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| EQX | -10.91% | $4.65B | 0.00% | 0.00% |
| AQB | -10.13% | $3.02M | -55.17% | 0.00% |
| UUU | -10.05% | $7.17M | +113.79% | 0.00% |
| SLP | -9.36% | $260.84M | -70.68% | 0.44% |
| GIII | -8.84% | $1.01B | -13.64% | 0.00% |
| GOOS | -8.83% | $1.35B | +15.20% | 0.00% |
| NIU | -8.64% | $241.14M | +59.45% | 0.00% |
| CASI | -7.90% | $20.14M | -79.56% | 0.00% |
| LULU | -7.19% | $26.63B | -23.84% | 0.00% |
| K | -6.71% | $27.56B | +39.23% | 2.87% |
| DY | -6.55% | $7.25B | +37.67% | 0.00% |
| GME | -6.48% | $10.39B | -18.64% | 0.00% |
| CREG | -5.88% | $5.79M | -77.35% | 0.00% |
| CME | -5.87% | $99.10B | +42.79% | 1.75% |
| YRD | -5.45% | $529.67M | +26.65% | 6.87% |
| AWK | -4.51% | $27.46B | +1.26% | 2.22% |
| AIFU | -4.47% | $20.27M | +118.75% | 0.00% |
| ED | -4.36% | $36.01B | +9.18% | 3.35% |
| PRPO | -4.33% | $22.35M | +232.88% | 0.00% |
| TEF | -4.32% | $29.18B | +18.85% | 6.34% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| SCHR | -0.01% | $10.84B | 0.03% |
| SMMU | -0.02% | $899.05M | 0.35% |
| GLD | 0.02% | $102.12B | 0.4% |
| OUNZ | 0.09% | $1.76B | 0.25% |
| UUP | -0.09% | $187.70M | 0.77% |
| AAAU | -0.10% | $1.57B | 0.18% |
| IBTL | -0.12% | $385.43M | 0.07% |
| TBIL | -0.13% | $5.74B | 0.15% |
| BAR | -0.13% | $1.13B | 0.1749% |
| TYA | 0.13% | $147.83M | 0.15% |
| SPTI | 0.14% | $8.66B | 0.03% |
| SGOL | -0.18% | $5.27B | 0.17% |
| FLGV | 0.19% | $1.02B | 0.09% |
| IBTM | 0.20% | $316.67M | 0.07% |
| IAU | -0.20% | $47.75B | 0.25% |
| TIPX | -0.20% | $1.74B | 0.15% |
| ICSH | -0.23% | $5.96B | 0.08% |
| STOT | 0.29% | $254.18M | 0.45% |
| WEAT | 0.30% | $122.74M | 0.28% |
| IBTK | -0.36% | $448.08M | 0.07% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| VIXY | -19.95% | $198.83M | 0.85% |
| BTAL | -19.46% | $310.74M | 1.43% |
| VIXM | -18.09% | $23.12M | 0.85% |
| TAIL | -16.96% | $94.79M | 0.59% |
| IVOL | -13.05% | $342.76M | 1.02% |
| GSST | -11.74% | $927.91M | 0.16% |
| CLIP | -10.56% | $1.51B | 0.07% |
| TPMN | -10.47% | $31.00M | 0.65% |
| TFLO | -10.45% | $6.74B | 0.15% |
| XONE | -6.87% | $629.19M | 0.03% |
| IBTH | -6.61% | $1.62B | 0.07% |
| GBIL | -6.05% | $6.37B | 0.12% |
| XBIL | -6.04% | $781.64M | 0.15% |
| BIL | -5.97% | $41.80B | 0.1356% |
| IBTF | -5.94% | $1.98B | 0.07% |
| BILS | -5.85% | $3.81B | 0.1356% |
| FXY | -5.73% | $793.88M | 0.4% |
| ULST | -5.44% | $590.76M | 0.2% |
| SCHO | -4.94% | $10.92B | 0.03% |
| JMST | -4.64% | $4.09B | 0.18% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| IBB | 33.66% | $5.48B | 0.45% |
| XBI | 33.23% | $5.07B | 0.35% |
| GNOM | 31.58% | $44.39M | 0.5% |
| PINK | 31.02% | $130.53M | 0.5% |
| PBE | 30.77% | $229.54M | 0.58% |
| ARKG | 30.46% | $1.06B | 0.75% |
| BBH | 30.24% | $339.74M | 0.35% |
| XPH | 29.82% | $168.46M | 0.35% |
| PTH | 29.81% | $96.01M | 0.6% |
| IWMY | 28.81% | $120.43M | 1.02% |
| VHT | 28.19% | $15.33B | 0.09% |
| FHLC | 27.92% | $2.43B | 0.084% |
| IYH | 27.32% | $2.73B | 0.39% |
| ARKK | 26.96% | $6.94B | 0.75% |
| IWC | 26.80% | $831.95M | 0.6% |
| XLV | 26.72% | $33.63B | 0.09% |
| FBT | 26.69% | $1.03B | 0.54% |
| RSPH | 26.57% | $718.84M | 0.4% |
| IXJ | 26.46% | $3.76B | 0.41% |
| RDTE | 26.29% | $138.45M | 0.97% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| VIV | -0.02% | $18.10B | +28.65% | 0.69% |
| BGFV | 0.03% | $32.58M | -50.00% | 0.00% |
| PULM | -0.05% | $22.50M | +193.33% | 0.00% |
| NTGR | -0.05% | $845.52M | +88.06% | 0.00% |
| HE | 0.07% | $1.80B | -13.98% | 0.00% |
| AGI | 0.08% | $11.07B | +47.89% | 0.38% |
| VSA | 0.08% | $12.16M | +18.21% | 0.00% |
| SAM | 0.11% | $2.13B | -33.39% | 0.00% |
| NHTC | 0.13% | $51.46M | -36.86% | 17.82% |
| FF | -0.16% | $180.47M | -22.41% | 5.76% |
| AWR | -0.16% | $2.88B | -5.67% | 2.49% |
| LTM | -0.17% | $12.66B | -95.54% | 2.41% |
| OR | 0.20% | $5.16B | +53.69% | 0.70% |
| SSL | 0.20% | $3.17B | -32.75% | 0.00% |
| SNBR | 0.20% | $166.33M | -28.60% | 0.00% |
| LESL | 0.20% | $74.28M | -90.21% | 0.00% |
| RLMD | 0.24% | $20.98M | -83.24% | 0.00% |
| PHYS.U | -0.25% | - | - | 0.00% |
| SPTN | -0.25% | $897.34M | +38.80% | 3.30% |
| YORW | 0.26% | $449.43M | -22.42% | 2.78% |
Finnhub
UroGen Pharma Ltd. 2024 ANNUAL REPORT ...
Yahoo
The trial has enrolled 99 subjects from various centres globally to assess the efficacy and safety of the therapy.
Yahoo
PRINCETON, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has completed patient enrollment in its Phase 3 UTOPIA clinical trial of UGN-103 (mitomycin) for intravesical solution, a next-generation formulation in development for the treatment of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG
Finnhub
UroGen Pharma Ltd. announced that it has completed patient enrollment in its Phase 3 UTOPIA clinical trial of UGN-103 for intravesical solution, a next-generation formulation in development for the...
Yahoo
UroGen Pharma Ltd. (NASDAQ:URGN) is one of the best hot stocks to buy according to Wall Street analysts. In mid-June, UroGen Pharma announced that the US FDA had approved ZUSDURI (mitomycin) for intravesical solution. This marked ZUSDURI as the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). ZUSDURI […]
Finnhub
NEW YORK, July 2, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against UroGen Pharma Ltd. . Such investors are advised to contact Danielle Peyton...
